Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Next steps for combination immunotherapies for RCC

Matthew Zibelman • 23 Feb 2022
GU Cancers 2022
Genitourinary Cancer Kidney Cancer Antibodies Axitinib Nivolumab

Matthew Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the future of combination immunotherapies for patients with renal cell carcinoma, and talks on some of the key unmet needs and research gaps in this field. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Matthew Zibelman

1:03
Potential of adjuvant therapy for RCC
Matthew Zibelman • 23 Feb 2022
1:29
Phase I/II study of nivolumab and axitinib for advanced RCC
Matthew Zibelman • 23 Feb 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals